scholarly journals Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis

PLoS ONE ◽  
2017 ◽  
Vol 12 (2) ◽  
pp. e0172120 ◽  
Author(s):  
Raed Behbehani ◽  
Abdullah Abu Al-Hassan ◽  
Ali Al-Salahat ◽  
Devarajan Sriraman ◽  
J. D. Oakley ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Optical Coherence Tomography ◽  
Progressive Multiple Sclerosis ◽  
Optical Coherence ◽  
Segmentation Analysis ◽  
Relapsing Remitting

scholarly journals Angiography with optical coherence tomography as a biomarker in multiple sclerosis

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0243236
Author(s):  
Beatriz Cordon ◽  
Elisa Vilades ◽  
Elvira Orduna ◽  
María Satue ◽  
Javier Perez-Velilla ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Optical Coherence Tomography ◽  
Healthy Subjects ◽  
Optical Coherence ◽  
Swept Source ◽  
Retinal Microvasculature ◽  
Potential Biomarker ◽  
Relapsing Remitting ◽  
Swept Source Oct ◽  
Retinal Vascularization

Purpose To investigate superficial retinal microvascular plexuses detected by optical coherence tomography angiography (OCT-A) in multiple sclerosis (MS) subjects and compare them with healthy controls. Methods A total of 92 eyes from 92 patients with relapsing-remitting MS and 149 control eyes were included in this prospective observational study. OCT-A imaging was performed using Triton Swept-Source OCT (Topcon Corporation, Japan). The vessel density (VD) percentage in the superficial retinal plexus and optic disc area (6 x 6 mm grid) was measured and compared between groups. Results MS patients showed a significant decrease VD in the superior (p = 0.005), nasal (p = 0.029) and inferior (p = 0.040) parafoveal retina compared with healthy subjects. Patients with disease durations of more than 5 years presented lower VD in the superior (p = 0.002), nasal (p = 0.017) and inferior (p = 0.022) parafoveal areas compared with healthy subjects. Patients with past optic neuritis episodes did not show retinal microvasculature alterations, but patients with an EDSS score of less than 3 showed a significant decrease in nasal (p = 0.024) and superior (p = 0.006) perifoveal VD when compared with healthy subjects. Conclusions MS produces a decrease in retinal vascularization density in the superficial plexus of the parafoveal retina. Alterations in retinal vascularization observed in MS patients are independent of the presence of optic nerve inflammation. OCT-A has the ability to detect subclinical vascular changes and is a potential biomarker for diagnosing the presence and progression of MS.

scholarly journals Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort

2017 ◽  
Vol 25 (1) ◽  
pp. 55-62 ◽  
Author(s):  
Kimberly M Winges ◽  
Charles F Murchison ◽  
Dennis N Bourdette ◽  
Rebecca I Spain
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trial ◽  
Optical Coherence Tomography ◽  
Brain Atrophy ◽  
Disease Duration ◽  
Progressive Multiple Sclerosis ◽  
Optical Coherence ◽  
Whole Brain ◽  
Secondary Progressive ◽  
Sd Oct

Background: Limited prospective information exists regarding spectral-domain optical coherence tomography (SD-OCT) in secondary progressive multiple sclerosis (SPMS). Objective: Document cross-sectional and longitudinal retinal nerve fiber layer (RNFL) and macular ganglion cell plus inner plexiform layer (GCIPL) features of an SPMS clinical trial cohort. Methods: Prospective, observational study using a 2-year randomized placebo-controlled SPMS trial cohort with yearly SD-OCT testing. Post hoc analysis determined influences of optic neuritis (ON), disease duration, and baseline SD-OCT on annualized atrophy rates and on correlations between OCT and brain atrophy. Results: Mean RNFL and GCIPL values of patients ( n = 47, mean age = 59 years, mean disease duration = 30 years) were significantly lower among eyes with prior ON than those without (no history of ON (NON)). Annualized RNFL (−0.31 µm/year) and GCIPL (−0.29 µm/year) atrophy rates did not differ between ON and NON eyes. Baseline RNFL thickness >75 µm was associated with greater annualized RNFL atrophy (−0.85 µm/year). Neither RNFL nor GCIPL atrophy correlated with whole-brain atrophy. Conclusion: This study suggests that eyes with and without ON history may be pooled for atrophy analysis in SPMS clinical trials using SD-OCT. Low baseline RNFL, small retinal atrophy rates, and lack of correlation with whole-brain atrophy in this population are important trial design considerations.

scholarly journals Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis

2020 ◽  
pp. 135245852096440
Author(s):  
Robert A Bermel ◽  
Janel K Fedler ◽  
Peter Kaiser ◽  
Cindy Novalis ◽  
Jeff Schneebaum ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Optical Coherence Tomography ◽  
Volume Change ◽  
Outcome Measure ◽  
Progressive Multiple Sclerosis ◽  
Inner Plexiform Layer ◽  
Optical Coherence ◽  
Double Blind ◽  
Thickness Change ◽  
Macular Volume

Background: The SPRINT-MS trial demonstrated benefit of ibudilast on brain atrophy over 96 weeks in progressive multiple sclerosis (MS). Optical coherence tomography (OCT) was performed in all trial participants. Objective: Report the OCT results of the SPRINT-MS trial. Methods: OCT was obtained at baseline and every 6 months using spectral domain OCT and analyzed by an OCT reading center. Change in each OCT outcome measure by treatment group was estimated using linear mixed models. Results: Change in pRNFL thickness was +0.0424 uM/year (95% confidence interval (CI): −0.3091 to 0.3939) for ibudilast versus −0.2630 uM (95% CI: −0.5973 to 0.0714) for placebo ( n = 244, p = 0.22). Macular volume change was −0.00503 mm3/year (−0.02693 to 0.01688) with ibudilast versus −0.03659 mm3/year (−0.05824 to −0.01494) for placebo in the Spectralis cohort ( n = 61, p = 0.044). For the Cirrus cohort, macular volume change was −0.00040 mm3/year (−0.02167, 0.020866) with ibudilast compared to −0.02083 mm3/year (−0.04134 to −0.00033) for placebo ( n = 183, p = 0.1734). Ganglion cell-inner plexiform layer thickness change, available from Cirrus, was −0.4893 uM/year (−0.9132, −0.0654) with ibudilast versus −0.9587 uM/year (−1.3677, −0.5498) with placebo ( n = 183, p = 0.12). Conclusion: Retinal thinning in MS may be attenuated by ibudilast. Sample size estimates suggest OCT can be a viable outcome measure in progressive MS trials if a therapy has a large treatment effect. Trial registration: NN102/SPRINT-MS ClinicalTrials.gov number, NCT01982942.

Sign in / Sign up

Export Citation Format

Share Document